The DOI matches its Crossref record, with a small difference in title or year; 28 of the 28 references it cites were found in a registry or an index.
C-Reactive Protein Levels and Outcomes after Statin Therapy
Open accessAbstract
BACKGROUND: Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown. METHODS: We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes. RESULTS: Patients in whom statin therapy resulted in LDL cholesterol levels of less than 70 mg per deciliter (1.8 mmol per liter) had lower event rates than those with higher levels (2.7 vs. 4.0 events per 100 person-years, P=0.008). However, a virtually identical difference was observed between those who had CRP levels of less than 2 mg per liter after statin therapy and those who had higher levels (2.8 vs. 3.9 events per 100 person-years, P=0.006), an effect present at all levels of LDL cholesterol achieved. For patients with post-treatment LDL cholesterol levels of more than 70 mg per deciliter, the rates of recurrent events were 4.6 per 100 person-years among those with CRP levels of more than 2 mg per liter and 3.2 events per 100 person-years among those with CRP levels of less than 2 mg per liter; the respective rates among those with LDL cholesterol levels of less than 70 mg per deciliter were 3.1 and 2.4 events per 100 person-years (P<0.001). Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Patients who had LDL cholesterol levels of less than 70 mg per deciliter and CRP levels of less than 1 mg per liter after statin therapy had the lowest rate of recurrent events (1.9 per 100 person-years). CONCLUSIONS: Patients who have low CRP levels after statin therapy have better clinical outcomes than those with higher CRP levels, regardless of the resultant level of LDL cholesterol. Strategies to lower cardiovascular risk with statins should include monitoring CRP as well as cholesterol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given that these parameters are well-established risk factors associated with differences in cardiovascular event rates in clinical trials, 26-28”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [26]
Experimental — accuracy not yet measuredIn the citing paper
“Fenofibrate reduces the progression of diabetic retinopathy [517,518].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [517]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citationIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citationRidker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Self-citationDanesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408183310701 · Cited by 2,354
Effect of Statin Therapy on C-Reactive Protein Levels
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,644
Self-citationRidker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Davignon J, 2004, Circulation, 109, III
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Behrouz, V., Sohrab, G., Hedayati, M., & Sedaghat, M. (2021) · Phytotherapy Research · doi:10.1002/ptr.7124 · Cited by 33
Anti-inflammatory Strategies in Atherosclerosis
Bugger, H., & Zirlik, A. (2021) · Hämostaseologie · doi:10.1055/a-1661-0020 · Cited by 32
Maierean, S. M., Webb, R. J., Banach, M., & Mazidi, M. (2022) · European Heart Journal Open · doi:10.1093/ehjopen/oeac039 · Cited by 32
Long-Term Prognostic Value of Preprocedural C-Reactive Protein After Drug-Eluting Stent Implantation
Delhaye, C., Maluenda, G., Wakabayashi, K., Ben‐Dor, I., Lemesle, G., Collins, S. D., Syed, A. I., Torguson, R., Kaneshige, K., Xue, Z., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.10.064 · Cited by 30
Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation
Ferri, N., Paoletti, R., & Corsini, A. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000245254.33011.de · Cited by 30
Nonlipid-lowering effects of statins
Sorrentino, S. A., & Landmesser, U. (2005) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-005-0031-1 · Cited by 31
Kai, T., Arima, S., Taniyama, Y., Nakabou, M., & Kanamasa, K. (2008) · Clinical and Experimental Hypertension · doi:10.1080/10641960802251925 · Cited by 30
Dark chocolate: consumption for pleasure or therapy?
Lippi, G., Franchini, M., Montagnana, M., Favaloro, E. J., Guidi, G. C., & Targher, G. (2008) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-008-0273-3 · Cited by 30
Shimada, K., Fujita, M., Tanaka, A., Yoshida, K., Jissho, S., Tanaka, H., Yoshikawa, J., Kohro, T., Hayashi, D., Okada, Y., et al. (2008) · Circulation Journal · doi:10.1253/circj.cj-08-0295 · Cited by 30
Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine
Anwaruddin, S., Askari, A. T., & Topol, E. J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.051 · Cited by 30
Early signaling of inflammation in acute ischemic stroke: Clinical and rheological implications
Shenhar‐Tsarfaty, S., Assayag, E. B., Bova, I., Shopin, L., Berliner, S. A., Shapira, I., & Bornstein, N. M. (2007) · Thrombosis Research · doi:10.1016/j.thromres.2007.10.019 · Cited by 30
Statins: immunomodulators for autoimmune rheumatic disease?
Jury, E. C., & Ehrenstein, M. R. (2005) · Lupus · doi:10.1191/0961203303lu2135oa · Cited by 30
Kornman, K. S., Rogus, J. J., Roh-Schmidt, H., Krempin, D., Davies, A. J., Grann, K., & Randolph, R. K. (2007) · Nutrition · doi:10.1016/j.nut.2007.08.005 · Cited by 30
Muro, F. M. D., Vogel, B., Sartori, S., Bay, B., Oliva, A., Feng, Y., Krishnan, P., Sweeny, J. M., Gitto, M., Smith, K. F., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf112 · Cited by 31
Bang, C. N., Greve, A. M., la Cour, M., Boman, K., Gohlke-Bärwolf, C., Ray, S. G., Pedersen, T., Rossebø, A. B., Okin, P. M., Devereux, R. B., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.09.026 · Cited by 29
Therapeutic Approaches Targeting Inflammation in Cardiovascular Disorders
Jones, D., & Patel, J. (2018) · Biology · doi:10.3390/biology7040049 · Cited by 30
Role of CD40(L)-TRAF signaling in inflammation and resolution—a double-edged sword
Strohm, L., Ubbens, H., Münzel, T. F., Daiber, A., & Daub, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.995061 · Cited by 29
The associations between exercise and lipid biomarkers
Sulague, R. M., Suan, N. M., Mendoza, M. F., & Lavie, C. J. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.004 · Cited by 32
The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review
Abohelwa, M., Kopel, J. J., Shurmur, S. W., Ansari, M. M., Awasthi, S., & Awasthi, S. (2023) · Journal of Vascular Diseases · doi:10.3390/jvd2010010 · Cited by 43
Explaining biological differences between men and women by gendered mechanisms
Colineaux, H., Neufcourt, L., Delpierre, C., Kelly‐Irving, M., & Lepage, B. (2023) · Emerging Themes in Epidemiology · doi:10.1186/s12982-023-00121-6 · Cited by 38
Evaluation of C-Reactive Protein Before and On-Treatment as a Predictor of Benefit of Atorvastatin
Sever, P., Poulter, N. R., Chang, C. L., Thom, S., Hughes, A. D., Welsh, P. I., & Sattar, N. A. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.098 · Cited by 29
Ho, K.-T., Chin, K.-W., Ng, K.-S., Alemao, E., Rajagopalan, S., & Yin, D. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606060-00005 · Cited by 29
Mulder, D. J., van Haelst, P. L., Wobbes, M. H., Gans, R. O. B., Zijlstra, F., May, J. F., Smit, A. J., Tervaert, J. W. C., & van Doormaal, J. J. (2007) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-007-6010-x · Cited by 32
Caixeta, A. M., Stone, G. W., Mehran, R., Lee, E. A., McLaurin, B. T., Cox, D. A., Bertrand, M. E., Lincoff, A. M., Moses, J. W., White, H. D., et al. (2010) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-010-0516-y · Cited by 29
Should C-Reactive Protein Be a Target of Therapy?
Oh, J., Teoh, H., & Leiter, L. A. (2011) · Diabetes Care · doi:10.2337/dc11-s211 · Cited by 30
Dosh, K., Berger, P. B., Marso, S. P., Lente, F. V., Brennan, D. M., Charnigo, R. J., Topol, E. J., & Steinhubl, S. R. (2009) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.109.879312 · Cited by 31
Inflammation during acute coronary syndromes — Risk of cardiovascular events and bleeding
Nanchen, D., Klingenberg, R., Gencer, B., Räber, L., Carballo, D., von Eckardstein, A., Windecker, S., Rodondi, N., Lüscher, T. F., Mach, F., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.03.049 · Cited by 29
Morrow, D. A., & Boden, W. E. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00057-3 · Cited by 28
Self-citationC‐reactive protein in patients with coexistent periodontal disease and acute coronary syndromes
Czerniuk, M. R., Górska, R., Filipiak, K. J., & Opolski, G. (2006) · Journal Of Clinical Periodontology · doi:10.1111/j.1600-051x.2006.00931.x · Cited by 29
Guidelines for the Use of Orexigenic Drugs in Long‐Term Care
Thomas, D. R. (2006) · Nutrition in Clinical Practice · doi:10.1177/011542650602100182 · Cited by 29
The Use of Biomarkers for the Evaluation and Treatment of Patients with Acute Coronary Syndromes
Saenger, A. K., & Jaffe, A. S. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.04.001 · Cited by 29
Matsuo, Y., Hashizume, T., Shioji, S., & Akasaka, T. (2008) · Circulation Journal · doi:10.1253/circj.cj-08-0337 · Cited by 29
Rodondi, N., Cornuz, J., Marques-Vidal, P. M., Butler, J., Hayoz, D., Pécoud, A. R., Paccaud, F. M., Waeber, G., & Vollenweider, P. (2007) · Preventive Medicine · doi:10.1016/j.ypmed.2007.08.006 · Cited by 28
C-reactive protein and cardiovascular disease: a critical appraisal
Sepulveda, J. L., & Mehta, J. L. (2005) · Current Opinion in Internal Medicine · doi:10.1097/01.hco.0000175518.57804.94 · Cited by 27
The Time for Cardiovascular Inflammation Reduction Trials Has Arrived
Ridker, P. M. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.168989 · Cited by 28
Self-citationSchoos, M. M., Kelbæk, H., Kofoed, K. F., Køber, L., Kløvgaard, L., Helqvist, S., Engstrøm, T., Saunamäki, K. I., Jørgensen, E. O., Holmvang, L., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.01.042 · Cited by 28
Kajinami, K., & Yasusyuki, K. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s13492 · Cited by 28
Fu, H., Wang, Q.-S., Luo, Q., Tan, S., Su, H., Tang, S., Zhao, Z.-L., & Huang, L.-P. (2014) · World Journal of Emergency Medicine · doi:10.5847/wjem.j.issn.1920-8642.2014.04.009 · Cited by 29
Hellberg, S., Sippola, S., Liljenbäck, H., Virta, J., Silvola, J. M. U., Ståhle, M. R., Savisto, N., Metso, J., Jauhiainen, M., Saukko, P. J., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.004 · Cited by 29
A Perspective on Targeting Inflammation and Cytokine Actions in Atherosclerosis
Chan, Y., & Ramji, D. P. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0301 · Cited by 29
Yu, Y., Yan, L., Lou, Y., Cui, R., Kang, K., Jiang, L., Mo, D., Gao, F., Wang, Y., Lou, X., et al. (2021) · Journal of neurosurgery · doi:10.3171/2021.6.jns211201 · Cited by 28
Secondary prevention strategies for coronary heart disease
Weiner, S. D., & Rabbani, L. E. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0381-8 · Cited by 28
Karalis, I. K., Bergheanu, S. C., Wolterbeek, R., Dallinga‐Thie, G. M., Hattori, H., van Tol, A., Liem, A. H., & Jukema, J. W. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.509264 · Cited by 28
Association Between C-Reactive Protein and Type 2 Diabetes in a Tunisian Population
Belfki, H., Ali, S. B., Bougatef, S., Ahmed, D. B., Haddad, N., Jmal, A., Abdennebi, M., & Romdhane, H. B. (2011) · Inflammation · doi:10.1007/s10753-011-9361-1 · Cited by 28
Τζιόμαλος, Κ., Dimitroula, H. V., Katsiki, N., Savopoulos, C. G., & Hatzitolios, A. I. (2010) · Mediators of Inflammation · doi:10.1155/2010/364957 · Cited by 28
Inamoto, S., Yoshioka, T., Yamashita, C., Miyamura, M., Mori, T., Ukimura, A., Matsumoto, C., Matsumura, Y., Kitaura, Y., & Hayashi, T. (2010) · Hypertension Research · doi:10.1038/hr.2010.36 · Cited by 30
Role of inflammation in retinal vein occlusion
Lee, H. B. H., Pulido, J. S., McCannel, C. A., & Buettner, H. (2007) · Canadian Journal of Ophthalmology · doi:10.1139/i06-101 · Cited by 28
Simon, R. W., van der Loo, B., Kovacevic, T., Brockes, C., Rousson, V., Amann-Vesti, B. R., Spring, S., & Koppensteiner, R. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-04-0265 · Cited by 28
Factores de riesgo cardiovascular
Rubiés-Prat, J. (2005) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(05)73753-x · Cited by 29
Lewis, S. J. (2010) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.109.880955 · Cited by 29
Derivation of Novel Risk Prediction Scores for Community-Acquired Sepsis and Severe Sepsis*
Wang, H. E., Donnelly, J. P., Griffin, R. L., Levitan, E. B., Shapiro, N. I., Howard, G., & Safford, M. M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001666 · Cited by 28
Ibáñez, L., Valls, C., & de Zegher, F. (2005) · Human Reproduction · doi:10.1093/humrep/dei329 · Cited by 28
SARS-CoV-2 infection and SLE: endothelial dysfunction, atherosclerosis, and thrombosis
Płazak, W., & Drabik, L. (2023) · Clinical Rheumatology · doi:10.1007/s10067-022-06497-1 · Cited by 27
Seo, S. M., Baek, S. H., Jeon, H. K., Kang, S., Kim, D., Kim, W.-S., Kim, H. S., Rha, S., Park, J., Seong, I. W., et al. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.16089 · Cited by 26
Horn, C. S., Ilg, R., Sander, K., Bickel, H., Briesenick, C., Hemmer, B., Poppert, H., & Sander, D. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5017-6 · Cited by 27
PAPP-A as a marker of increased long-term risk in patients with chest pain
Kavsak, P. A., Wang, X., Henderson, M., Ko, D. T., MacRae, A. R., & Jaffe, A. S. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.03.015 · Cited by 27
The role of inflammation in atherothrombosis: implications for clinical practice
Tedgui, A. (2005) · Vascular Medicine · doi:10.1191/1358863x05vm589ra · Cited by 27
Rossignoli, A., Shang, M.-M., Gladh, H., Moessinger, C., Asl, H. F., Talukdar, H. A., Franzén, O., Mueller, S., Björkegren, J., Folestad, E. B., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308715 · Cited by 27
Statins in the spectrum of neurologic disease
Orr, J. D. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-008-0003-5 · Cited by 27
Hypolipidemic therapy for the metabolic syndrome
Cignarella, A., Bellosta, S., Corsini, A., & Bolego, C. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.03.012 · Cited by 27
Barderas, M. G., Tuñón, J., Dardé, V. M., de la Cuesta, F., Jimenez-Nacher, J. J., Tarín, N., López‐Bescós, L., Egido, J., & Vivanco, F. (2009) · PROTEOMICS · doi:10.1002/pmic.200700583 · Cited by 28
Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution?
Abbate, A., & Dinarello, C. A. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu369 · Cited by 27
Koskinas, K. C., Windecker, S., Buhayer, A., Gencer, B., Pedrazzini, G., Mueller, C., Cook, S., Muller, O., Matter, C. M., Räber, L., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23112 · Cited by 26
Jahromi, G. P., Seidi, S., Sadr, S. S., Shabanzadeh, A. P., Keshavarz, M., Kaka, G. R., Hosseini, S.-M.-R., Sohanaki, H., & Charish, J. (2011) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2011.00848.x · Cited by 26
Expansion of T-Cell Receptor ζ dim Effector T Cells in Acute Coronary Syndromes
Ammirati, E., Vermi, A.-C., Cianflone, D., Banfi, M., Foglieni, C., Godino, C., Airoldi, F., Ferri, L., Gorman, C., Manfredi, A. A., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.174144 · Cited by 26
Montarello, N. J., Singh, K., Sinhal, A. R., Wong, D. T. L., Alcock, R. F., Rajendran, S., Dautov, R. F., Barlis, P., Patel, S., Nidorf, S. M., et al. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07240-9 · Cited by 26
Miyauchi, K., & Daida, H. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0565 · Cited by 26
Effect of Fresh Orange Juice Intake on Physiological Characteristics in Healthy Volunteers
Asgary, S., Keshvari, M., Afshani, M. R., Amiri, M., Laher, I., & Javanmard, S. H. (2014) · ISRN Nutrition · doi:10.1155/2014/405867 · Cited by 28
Hollar, D. (2013) · Disability and health journal · doi:10.1016/j.dhjo.2013.01.009 · Cited by 26
Defining a Role for Novel Biomarkers in Acute Coronary Syndromes
Bonaca, M. P., & Morrow, D. A. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105387 · Cited by 26
Self-citationdeFilippi, C. R., Toribio, M. P., Wong, L. P., Sadreyev, R. I., Grundberg, I., Fitch, K. V., Zanni, M. V., Lo, J., Sponseller, C. A., Sprecher, E., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa196 · Cited by 26
Zawadzki, C., Susen, S., Richard, F., Haulon, S., Corseaux, D., Jeanpierre, E., Vincentelli, A., Lucas, C., Torpier, G., Martin-Ponthieu, A., et al. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.10.012 · Cited by 29
Atherosclerotic Renal Artery Stenosis: Association with Emerging Vascular Risk Factors
Paraskevas, K. I., Hamilton, G., Cross, J. M., & Mikhailidis, D. P. (2007) · Nephron Clinical Practice · doi:10.1159/000112556 · Cited by 26
Pitavastatin: evidence for its place in treatment of hypercholesterolemia
Alagona, P. (2010) · Core evidence · doi:10.2147/ce.s8008 · Cited by 26
Microalbuminuria and C-reactive protein: Similar messengers of cardiovascular risk?
Bakker, S. J. L., Gansevoort, R. T., Stuveling, E. M., Gans, R. O. B., & de Zeeuw, D. (2005) · Current Hypertension Reports · doi:10.1007/s11906-005-0075-3 · Cited by 26
Yamazaki, D., Ishida, M., Watanabe, H., Nobori, K., Oguma, Y., Terata, Y., Koyama, T., Iino, K., Kosaka, T., & Ito, H. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-9 · Cited by 26
HIV-Infektion, antiretrovirale Therapie und Endothel
Hürlimann, D., Weber, R. K., Enseleit, F., & Lüscher, T. F. (2005) · Herz · doi:10.1007/s00059-005-2740-3 · Cited by 26
Seligowski, A. V., Grewal, S., Abohashem, S., Zureigat, H., Qamar, I., Aldosoky, W., Gharios, C., Hanlon, E. C., Alani, O., Bollepalli, S. C., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.01.006 · Cited by 27
Differential Metabolic Actions of Specific Statins: Clinical and Therapeutic Considerations
Lim, S. K., Sakuma, I., Quon, M. J., & Koh, K. K. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5531 · Cited by 25
Cardiovascular Risk Factors and Disease in Women
Gill, S. K. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.01.007 · Cited by 25
Cui, C.-J., Li, S., Zhu, C., Sun, J., Du, Y., Zhang, Y., Wu, N., Guo, Y., Xu, R., Gao, Y., et al. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12931 · Cited by 25
Bhatt, S. P., Guleria, R., Vikram, N. K., & Gupta, A. (2018) · Sleep And Breathing · doi:10.1007/s11325-018-1678-7 · Cited by 26
Whole blood viscosity in microvascular angina and coronary artery disease: Significance and utility
Çekirdekçi, E. İ., & Buğan, B. (2020) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repc.2019.04.008 · Cited by 30
Update on the Inflammatory Hypothesis of Coronary Artery Disease
Boland, J. L., & Long, C. S. (2021) · Current Cardiology Reports · doi:10.1007/s11886-020-01439-2 · Cited by 25
The role of lovastatin in the attenuation of COVID-19
Karampoor, S., Hesamizadeh, K., Shams, Z., Novin, A. G., Farahmand, M., Zahednasab, H., Mirzaei, R., Zamani, F., Hajibaba, M., Bouzari, B., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108192 · Cited by 25
Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases
Kao, T., & Huang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020804 · Cited by 23
Stroes, E. S. G., Bays, H. E., Banach, M., Catapano, A. L., Duell, P. B., Laufs, U., Mancini, G. B. J., Ray, K. K., Sasiela, W. J., Zhang, Y., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.020 · Cited by 26
Proteomic biomarkers for diagnosis in acute myocardial infarction
Park, J. P., Park, M. K., & Yun, J. W. (2010) · Biomarkers · doi:10.3109/1354750x.2010.515688 · Cited by 25
Alsheikh-Ali, A. A. A., & Karas, R. H. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0016-8 · Cited by 25
Oh, B., Kim, T. Y., Min, H. J., Kim, M., Kang, M. S., Huh, J. Y., Kim, Y., & Lee, D. S. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32835a0fbd · Cited by 25
Jeremias, A., Soodini, G. R., Gelfand, E. V., Xu, Y., Stanton, R. C., Horton, E. S., & Cohen, D. J. (2009) · Heart International · doi:10.4081/hi.2009.e7 · Cited by 25
Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?
Reklou, A., Doumas, M. N., Imprialos, K. P., Stavropoulos, K., Patoulias, D., & Athyros, V. G. (2018) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401812010029 · Cited by 26
PentraSorb C‐Reactive Protein: Characterization of the Selective C‐Reactive Protein Adsorber Resin
Mattecka, S., Brunner, P., Hähnel, B., Kunze, R., Vogt, B., & Sheriff, A. (2019) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12796 · Cited by 27
Kang, D. O., Park, Y., Seo, J. H., Jeong, M. H., Chae, S. C., Ahn, T. H., Jang, W. Y., Kim, W., Park, E. J., Choi, B. G., et al. (2019) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.12.022 · Cited by 25
Kurose, S., Iwasaka, J., Tsutsumi, H., Yamanaka, Y., Shinno, H., Fukushima, Y., Higurashi, K., Imai, M., Masuda, I., Takeda, S., et al. (2015) · Heart and Vessels · doi:10.1007/s00380-015-0681-1 · Cited by 25
Residual risk in statin-treated patients: Future therapeutic options
Campbell, C. Y., Rivera, J. J., & Blumenthal, R. S. (2007) · Current Cardiology Reports · doi:10.1007/bf02938395 · Cited by 26
Stefanadis, C., Toutouzas, K. P., Tsiamis, E. G., Vavuranakis, M., Tsioufis, C. P., Stefanadi, E., & Boudoulas, H. K. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.05.038 · Cited by 25
Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials
Ray, K. K., & Cannon, C. P. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.6.915 · Cited by 25
Self-citationSixt, S., Beer, S., Bluher, M., Korff, N., Peschel, T., Sonnabend, M., Teupser, D., Thiery, J., Adams, V., Schuler, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp398 · Cited by 122
Metadata
- Authors
- Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E.
- Affiliations
- Brigham and Women's Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-01-06
- Volume
- 352
- Issue
- 1
- Pages
- 20-28
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118154631
- Cited by
- 2,292
- References
- 28
- Citations by year
- 2026: 32 · 2025: 46 · 2024: 47 · 2023: 52 · 2022: 70 · 2021: 58 · 2020: 74 · 2019: 64 · 2018: 72 · 2017: 54 · 2016: 78 · 2015: 62 · 2014: 67 · 2013: 93 · 2012: 88
- FWCI
- 282.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- C-reactive protein, statin therapy, LDL cholesterol, atorvastatin, pravastatin, acute coronary syndrome, reinfarction, coronary death, cardiovascular risk, lipid-lowering targets
- MeSH terms
- Atorvastatin, Gatifloxacin, Anticholesteremic Agents, C-Reactive Protein, Coronary Disease, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Pyrroles, Risk Factors, Biomarkers, Incidence, Proportional Hazards Models, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Fluoroquinolones, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
